Logo


XCyton launches therapeutic decision support system

XCyton, a molecular biology company, has developed the Syndrome Evaluation System (SES) that allows for the immediate identification of multiple organisms in a specific test from a single sample that provides the clinician with an assessment of a patient. The Syndrome Evaluation System (SES) has been announced by XCyton Diagnostics, a diagnostic product development company with a focus on molecular biology. Kiran Mazumdar Shaw, CMD of Biocon, has personally invested in XCyton. Commercially-available conventional tests like bacterial and fungal cultures, viral cultures or immunological tests ...